Eyenovia’s Earnings Call Contradicts Itself: Unpredictable Airdrops vs. 2026 Profit Targets, Shifting Revenue Models

Date of Call: Mar 26, 2026

Guidance:

• Adjusted gross profit expected to grow in each quarter of 2026, ending the year at levels greater than the start.
• Expect positive net operating cash flow by the end of 2026.
• Staking and Validator revenues expected to increase as Hyperliquid network expands.
• Yield enhancement strategies to scale with new Vault partnership and private lending pools.
• Pipeline for DeFi monetization and protocol partnerships is robust, with potential new opportunities from HIP4 upgrade.
• Anticipate additional air drops and ecosystem rewards in 2026.

Business Commentary:

Revenue Growth and DeFi Strategy:

• Hyperion DeFi reported an 87% quarter-over-quarter increase in adjusted gross profit, rising from $439,000 in Q3 to $821,000 in Q4.
• This growth was driven by the execution of a comprehensive DeFi strategy, including staking, Validator operations, yield enhancement, DeFi monetization, and ecosystem rewards.

Staking and Validator Operations:

• Staking yield resulted in 8,700 HYPE tokens in Q4, a 17% increase quarter-over-quarter, despite a 10% decline in dollar value due to a drop in HYPE price.
• Validator commissions surged with 1,400 HYPE tokens earned in Q4, a 197% increase, due to a growing number of delegated tokens and strategic partnerships.

Ecosystem Rewards and Partnerships:

• Hyperion received 1.9 million KNTQ tokens from Kinetiq in Q4, marking the first significant ecosystem rewards, with potential additional rewards expected in 2026.
• This was attributed to active participation in the Hyperliquid DeFi ecosystem and strategic partnerships with key protocols like Kinetiq and Rysk.

HAUS and Market Expansion:

• The HYPE Asset Use Service (HAUS) saw substantial growth with the launch of HIP3 markets, contributing to revenue streams from trading activities.
• The expansion into non-crypto asset exchanges and partnerships with protocols like Felix and Silhouette enhanced revenue opportunities.

Cost Management and Expense Reduction:

• Core operating expenses declined 30% quarter-over-quarter, from $4.3 million in Q3 to $3.0 million in Q4.
• This reduction was achieved through scaling efficiencies and the potential for further cost reductions with the pending monetization of the Optejet LOI.

Sentiment Analysis:

Overall Tone: Positive

• CEO stated '2025 was a remarkable year of firsts' and that results 'transcended the strategy and capabilities of a simple buy-and-hold DAF.' CFO highlighted Q4 adjusted gross profit grew 87% quarter-over-quarter, exceeding prior guidance. CEO expressed conviction in the 'future is bright for Hyperliquid' and that Hyperion is 'building for the future of finance.'

Q&A:

• Question from Gareth Gacetta (Cantor Fitzgerald): I was wondering if you could go into more detail on the HAUS agreements you guys have for HIP3 markets and maybe how you're thinking about HIP4 and if you might participate similarly to how you've done with HIP3.
  Response: HAUS agreements for HIP3 generate dollar-denominated revenue via a share of trading fees. For HIP4, management will look to participate if there is an opportunity, given the HYPE on the balance sheet.

• Question from Gareth Gacetta (Cantor Fitzgerald): Could you maybe talk about where you might expect some of these to be more consistent or recurring in nature as compared to maybe some that might be less predictable?
  Response: Staking and Validator commissions are scalable; DeFi monetization and yield enhancement can scale parabolically; ecosystem rewards are inherently unpredictable but position the company uniquely.

• Question from Brett Knoblauch (Cantor Fitzgerald): At what point do you think growth mode kind of goes away and the fee potential of those markets starts to become more material for both you and the ecosystem from a buyback perspective?
  Response: Growth mode (90% fee reduction) is currently necessary to be competitive vs. traditional exchanges. As product base expands and user growth increases, fees are expected to come down over time.

• Question from Brett Knoblauch (Cantor Fitzgerald): Do you guys have any thoughts on [the U.S. Clarity Act] and maybe the potential where we see Hyperliquid eventually become allowed in the U.S. Is that something that you guys envision happening anytime soon?
  Response: Believe long-term regulatory arc will be supportive of Hyperliquid's access and growth, but do not have a crystal ball. Will continue to operate responsibly in the current environment.

• Question from James McIlree (Chardan Capital Markets): David, could you comment on operating cash flow breakeven for the year? And then secondly, the adjusted gross profit expectation that you have for the year, it kind of sounds like it's back-end loaded. I mean, not too much, but it does kind of sound back-end loaded. Is that correct?
  Response: Operating cash flow breakeven is expected in 2026 as DeFi businesses ramp and costs from the Optejet LOI are realized. Adjusted gross profit is expected to ramp each quarter, though not back-end loaded, with year-end run rates higher than the start.

• Question from James McIlree (Chardan Capital Markets): On the Silhouette announcement that you had yesterday, the day before, is that a similar revenue and earnings opportunity for you that you've had with the others that there's going to be a revenue share and maybe something else attached to it? And then when do you think that, that would become operational for you?
  Response: Silhouette offers a revenue share model based on trading fee reductions, similar to other HAUS deals, and is already operational with assets in trading accounts rising post-deal.

• Question from Unknown Analyst (Unknown Firm): Just can we just talk about the pipeline of Capital-as-a-Service agreements, your HAUS agreements? Talk about what you're typically looking for in a partner? And maybe how much capital you have ready to deploy into those...
  Response: There is a substantial pipeline for HYPE asset use. The company focuses on optimizing returns across strategies, utilizing the ATM to grow the HYPE position for scaling and compounding deals.

• Question from Unknown Analyst (Unknown Firm): Could you just talk about those HYPE-on-HYPE returns of some of the agreements you've made so far? And maybe just for fun, we could think of the HIP3 business as if growth mode were to end at some point and maybe volumes sustain?
  Response: Most HAUS agreements are dollar-based revenue (e.g., Silhouette fee reductions). For HIP3, without growth mode, the volume-based projections prior to deployment were accurate, and more trading activity would directly increase revenue.

Contradiction Point 1

Nature and Predictability of Revenue Streams

Contradiction on whether core business lines are scalable, recurring, or inherently unpredictable.

What are your thoughts on the company's recent financial results? - Gareth Gacetta (Cantor Fitzgerald)

20260326-2025 Q4: Staking yield scales with HYPE ownership. Validator commissions grow with delegated tokens... DeFi monetization can scale parabolically... Yield enhancement is linear... Ecosystem rewards are inherently unpredictable in timing but are a unique advantage... - [David Knox](CFO)

Which business lines are expected to be more consistent/recurring versus less predictable? - Unknown - referred to as "This 1 is regarding..."

20251114-2025 Q3: Hyperion DeFi... runs its own top 10 validator... actively uses staked HYPE to deploy into the ecosystem through various strategies... These strategies create a compounding flywheel effect, generating real revenue... - [Hyunsu Jung](CEO)

Contradiction Point 2

Operational Status and Financial Impact of Ecosystem Rewards

Contradiction on the materiality and financial impact of ecosystem rewards (airdrops).

James McIlree (Chardan Capital Markets) - James McIlree (Chardan Capital Markets)

20260326-2025 Q4: Adjusted gross profit is expected to ramp throughout 2026... The company is not giving specific quarterly guidance but expects all business lines to grow year-over-year. - [David Knox](CFO)

Could you comment on the operating cash flow breakeven for the year and confirm if the adjusted gross profit expectation is back-end loaded? - Unknown - referred to as "This 1 is regarding the Kinetiq air drop. Is that baked into our forecast?"

20251114-2025 Q3: The company believes it will be eligible for the Kinetiq token generation event (airdrop) but does not know the financial implications or if it will be material. They have not positioned their balance sheet or operations specifically to take advantage of it. - [David Knox](CFO)

Contradiction Point 3

Revenue and Profitability Timeline

Timeline for achieving meaningful revenue and profitability appears to have shifted significantly.

James McIlree (Chardan Capital Markets) - James McIlree (Chardan Capital Markets)

20260326-2025 Q4: Operating cash flow breakeven is a key target for 2026. - [Hyunsu Jung](CEO)

Could you comment on the operating cash flow breakeven for the year and confirm if the adjusted gross profit expectation is back-end loaded? - Lachlan Hanbury-Brown (William Blair)

2024Q3: Q3 revenue was ~$2,000, reflecting a loss on sales... The launch also sets up future growth for clobetasol. - [Andrew Jones](CFO) and [Michael Rowe](CEO)

Contradiction Point 4

Nature of Revenue Streams

The description of primary revenue sources has changed from product sales to protocol revenue sharing.

Gareth Gacetta (Cantor Fitzgerald) - Gareth Gacetta (Cantor Fitzgerald)

20260326-2025 Q4: The HYPE Asset Use Service (HAUS) allows Hyperion to earn a revenue share from HIP3 markets... The model is revenue share based... - [Hyunsu Jung](CEO)

Can you provide more details on the HAUS agreements for HIP3 markets and discuss your strategy for HIP4, including whether participation will be similar to HIP3? - Lachlan Hanbury-Brown (William Blair) – Follow-up:

2024Q3: The launch also sets up future growth for clobetasol. Strong interest and reorders are already occurring. - [Michael Rowe](CEO)

Contradiction Point 5

Regulatory and Market Outlook

Regulatory optimism contradicts the absence of concrete near-term plans.

Brett Knoblauch (Cantor Fitzgerald) - Brett Knoblauch (Cantor Fitzgerald)

20260326-2025 Q4: Long-term, Hyperion believes regulators and consumers are aligned... which will drive demand for Hyperliquid. The company does not have a crystal ball for specific regulatory timing but expects long-term upside from supportive regulatory tailwinds. - [David Knox](CFO)

Does the company envision Hyperliquid being allowed in the U.S. under the Clarity Act in the near future? - Matthew Kaplan (Ladenburg Thalmann)

2024Q2: After a positive efficacy analysis in Q4, an FDA meeting is requested (early 2025), with a 1-year safety commitment (Sep/Oct 2025). Full NDA submission would follow in late 2025, with a target approval in mid-to-late 2026. - [Michael Rowe](CEO)